Kask A, Rägo L, Harro J
Department of Pharmacology, University of Tartu, Estonia.
Eur J Pharmacol. 1996 Dec 19;317(2-3):R3-4. doi: 10.1016/s0014-2999(96)00838-2.
The effect of the novel non-peptide neuropeptide Y Y1 receptor antagonist BIBP3226, N2-(diphenylacetyl)-N-[(4-hydroxy-phenyl)-methyl]-D-arginine amide, on exploratory behaviour of rats in the elevated plus-maze was studied. BIBP3226 (0.5 and 5 micrograms, i.c.v.) induced an anxiogenic-like effect at the higher dose tested. This effect was antagonised by diazepam (0.5 mg/kg). The anxiogenic-like effect of BIBP3226 was not related to a decrease in general locomotor activity. These findings support the hypothesis that neuropeptide Y Y1 receptor subtype is involved in anxiety regulation.
研究了新型非肽类神经肽Y Y1受体拮抗剂BIBP3226（N2 -（二苯基乙酰基）-N - [（4 - 羟基苯基）-甲基]-D - 精氨酸酰胺）对大鼠在高架十字迷宫中探索行为的影响。BIBP3226（0.5微克和5微克，脑室内注射）在测试的较高剂量下诱导出类似焦虑的效应。地西泮（0.5毫克/千克）可拮抗这种效应。BIBP3226的类似焦虑效应与总体运动活动的降低无关。这些发现支持神经肽Y Y1受体亚型参与焦虑调节的假说。
